DE602004024188D1 - Des opioid-rezeptors - Google Patents

Des opioid-rezeptors

Info

Publication number
DE602004024188D1
DE602004024188D1 DE602004024188T DE602004024188T DE602004024188D1 DE 602004024188 D1 DE602004024188 D1 DE 602004024188D1 DE 602004024188 T DE602004024188 T DE 602004024188T DE 602004024188 T DE602004024188 T DE 602004024188T DE 602004024188 D1 DE602004024188 D1 DE 602004024188D1
Authority
DE
Germany
Prior art keywords
derivatives
disorders
subject invention
opioid receptor
conditions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004024188T
Other languages
German (de)
English (en)
Inventor
Jotham Wadsworth Coe
Stanton Furst Mchardy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of DE602004024188D1 publication Critical patent/DE602004024188D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE602004024188T 2003-04-14 2004-04-02 Des opioid-rezeptors Expired - Lifetime DE602004024188D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46260503P 2003-04-14 2003-04-14
PCT/IB2004/001237 WO2004089909A1 (en) 2003-04-14 2004-04-02 2-azabicyclo[3.3.1]nonane derivatives as opioid receptor antagonists

Publications (1)

Publication Number Publication Date
DE602004024188D1 true DE602004024188D1 (de) 2009-12-31

Family

ID=33159854

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004024188T Expired - Lifetime DE602004024188D1 (de) 2003-04-14 2004-04-02 Des opioid-rezeptors

Country Status (11)

Country Link
US (2) US7056930B2 (https=)
EP (1) EP1615893B1 (https=)
JP (1) JP4493648B2 (https=)
AT (1) ATE449074T1 (https=)
BR (1) BRPI0409369A (https=)
CA (1) CA2522180C (https=)
DE (1) DE602004024188D1 (https=)
DK (1) DK1615893T3 (https=)
ES (1) ES2334570T3 (https=)
MX (1) MXPA05011060A (https=)
WO (1) WO2004089909A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1440059B1 (en) * 2001-10-22 2008-04-16 Pfizer Products Inc. 3-azabicyclo(3.1.0)hexane derivatives as opioid receptor antagonists
BRPI0409307A (pt) * 2003-04-14 2006-04-25 Pfizer Prod Inc derivados de 3-azabiciclo[3.2.1]octano
US20050043345A1 (en) * 2003-08-22 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
MY145633A (en) 2006-03-01 2012-03-15 Theravance Inc 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
TWI409067B (zh) 2007-02-28 2013-09-21 Theravance Inc ８-氮雜雙環〔３．２．１〕辛烷化合物之結晶型
TWI425945B (zh) * 2007-05-28 2014-02-11 Seldar Pharma Inc 四氫異喹啉－１－酮衍生物或其鹽
US7947710B2 (en) * 2007-08-27 2011-05-24 Theravance, Inc. Disubstituted alkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
WO2009029252A1 (en) * 2007-08-27 2009-03-05 Theravance, Inc. Amidoalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
US7691878B2 (en) * 2007-08-27 2010-04-06 Theravance, Inc. Heteroarylalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
TWI423801B (zh) * 2007-08-27 2014-01-21 Theravance Inc 作為μ類鴉片受體拮抗劑之８－氮雜雙環〔３．２．１〕辛基－２－羥基苯甲醯胺化合物
GB0721178D0 (en) * 2007-10-29 2007-12-05 Glaxo Group Ltd Chemical compounds
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
US9663463B2 (en) * 2013-11-20 2017-05-30 Sanwa Kagaku Kenkyusho Co., Ltd. 3-azabicyclo[3.1.0]hexane derivative and use thereof for medical purpose
KR20180004734A (ko) * 2015-05-20 2018-01-12 가부시키가이샤산와카가쿠켄큐쇼 신규 3-아자비시클로［3.1.0］헥산 유도체의 염의 결정 및 그의 의약 용도
WO2017210105A1 (en) * 2016-06-02 2017-12-07 Virginia Commonwealth University Dual modulators of both mu and kappa opioid receptors
SG11202007422QA (en) 2018-02-05 2020-09-29 Alkermes Inc Compounds for the treatment of pain
US11352365B2 (en) 2018-03-19 2022-06-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Biased potent opioid-like agonists as improved medications to treat chronic and acute pain and methods of using the same
KR102266854B1 (ko) * 2019-11-06 2021-06-18 계명대학교 산학협력단 마약 중독 예방 또는 치료용 약학조성물

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2143145A (en) * 1934-11-06 1939-01-10 Farnsworth Television Inc Projection means
US6559159B2 (en) * 2001-02-01 2003-05-06 Research Triangle Institute Kappa opioid receptor ligands

Also Published As

Publication number Publication date
JP4493648B2 (ja) 2010-06-30
MXPA05011060A (es) 2005-12-12
ATE449074T1 (de) 2009-12-15
DK1615893T3 (da) 2010-01-18
EP1615893B1 (en) 2009-11-18
ES2334570T3 (es) 2010-03-12
USRE40838E1 (en) 2009-07-07
CA2522180A1 (en) 2004-10-21
JP2006522797A (ja) 2006-10-05
EP1615893A1 (en) 2006-01-18
BRPI0409369A (pt) 2006-04-25
US20040204445A1 (en) 2004-10-14
WO2004089909A1 (en) 2004-10-21
US7056930B2 (en) 2006-06-06
CA2522180C (en) 2009-12-08

Similar Documents

Publication Publication Date Title
DE602004024188D1 (de) Des opioid-rezeptors
MXPA05011018A (es) Compuestos de 4-fenil piperidna y sus usos como moduladores de receptores opioides.
PY0225353A (es) Derivados del 3-azabiciclo [3.1.0] hexano
DE602006009773D1 (de) Substituierte thiophenderivate als glucagonrezeptorantagonisten, herstellung und therapeutische anwendungen
DK1377586T3 (da) Tricykliske diazepiner som tocolytiske oxytocinreceptorantagonister
NO20082350L (no) Piperidin-4-YL-pyridazin-3-ylamin derivat som rask dissosiasjon dopamin 2-reseptor antagonister
MY143581A (en) Carboxamide derivatives as muscarinic receptor antagonists
ATE293448T1 (de) Benzo(d)azepin-derivative als 5-ht6-rezeptor- antagonisten
TW200508203A (en) 3-azabicyclo 3.2.1 octane derivatives
WO2006044293A3 (en) Bicyclic compounds as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders
DE602005014566D1 (de) Chinolinon-carboxamid-verbindungen
WO2007081995A3 (en) Urotensin ii receptor antagonists
EA200970553A1 (ru) Пиперидиниламинопиридазины и их применение в качестве быстро диссоциирующих антагонистов рецептора допамина 2
WO2006120478A3 (en) Quinoline derivatives as neurokinin receptor antagonists
EA200600688A1 (ru) Арилинденпиридины и арилинденпиримидины и их применение в качестве антагонистов аденозинового рецептора а2а
ATE307814T1 (de) Neue pyridin- und cyclohexenyl-enthaltende pyrrolobenzodiazepin-carboxamide und derivative davon; tokolytische oxytocin-rezeptor- antagonisten
WO2005035504A3 (en) 5-h -benzo [d] naphth [2, 1-b] azepine derivative as selective d1/d5 receptor antagonists for the treatment of obesity and cns disorders
HRP20050554B1 (hr) Supstituirani 1- piperidin-3-il-4-piperidin-4-il-piperazinski derivati i njihova primjena kao neurokininskih antagonista
DE602004018844D1 (de) Als antagonisten des muscarinrezeptors geeignete xanthinderivate
WO2005063697A3 (en) Substituted n-aryl amidines as selective d1 dopamine receptor antagonists for the treatment of obesity and cns disorders
DOP2004000878A (es) Derivados de 3-azabiciclo[3.2.1]octano
DE602005013094D1 (de) Chinolinderivate als neurokininrezeptor-antagonisten
AU2003262926A1 (en) Selective d1/d5 receptor antagonists for the treatment of obesity and cns disorders
WO2008093920A3 (en) 1,2-dihydro-1-oxophthalazinyl derivatives having biological activity on serotonin receptors 5-ht2a and 5-ht2c, and preparation thereof

Legal Events

Date Code Title Description
8364 No opposition during term of opposition